These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37354260)

  • 1. Durable benefit after treatment of obstructive benign prostatic hyperplasia with a novel drug-device combination product: 2-year outcomes from the EVEREST-I study.
    Pichardo M; Rijo E; Espino G; Lay RR; Estrella R; Gonzalez C; Fernandez M; Soriano D; Peralta IM; Kaplan SA
    World J Urol; 2023 Aug; 41(8):2209-2215. PubMed ID: 37354260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE Study).
    Kaplan SA; Moss JL; Freedman SJ
    Prostate Cancer Prostatic Dis; 2024 Sep; 27(3):531-536. PubMed ID: 38684918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PINNACLE Study: A Double-blind, Randomized, Sham-controlled Study Evaluating the Optilume BPH Catheter System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
    Kaplan SA; Moss J; Freedman S; Coutinho K; Wu N; Efros M; Elterman D; D'Anna R; Padron O; Robertson KJ; Lawindy S; Mistry S; Shore N; Spier J; Kaminetsky J; Mazzarella B; Cahn D; Jalkut M; Te A
    J Urol; 2023 Sep; 210(3):500-509. PubMed ID: 37555604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year outcomes after treatment with a drug-coated balloon catheter system for lower urinary tract symptoms related to benign prostatic hyperplasia.
    Kaplan SA; Pichardo M; Rijo E; Espino G; Lay RR; Estrella R
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1073-1079. PubMed ID: 33833379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes after treatment with Optilume BPH Four-year results from the EVEREST study.
    Kaplan SA; Pichardo M; Rijo E; Espino G; Lay RR; Estrella R
    Can Urol Assoc J; 2024 Nov; 18(11):E319-E325. PubMed ID: 38976898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up.
    Porpiglia F; Fiori C; Bertolo R; Garrou D; Cattaneo G; Amparore D
    BJU Int; 2015 Aug; 116(2):278-87. PubMed ID: 25382816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up.
    Porpiglia F; Fiori C; Amparore D; Kadner G; Manit A; Valerio M; Nicolaas L; Ho BSH; Alonso S; Schulman C; Barber N
    BJU Int; 2019 Jun; 123(6):1061-1069. PubMed ID: 30382600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-man Safety and Efficacy of the ClearRing Implant for the Treatment of Benign Prostatic Hyperplasia.
    Vjaters E; Nitsan D; Mullerad M; Engelstein D; Leibovitch I; Feld Y
    Eur Urol Focus; 2020 Jan; 6(1):131-136. PubMed ID: 30293945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
    Woo HH; Huang CP; Huang WJ; Chang YH; Lien CS; Chkhotua A; Elterman DS
    Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):576-582. PubMed ID: 35641601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GreenLight laser photoselective vaporization of the prostate for treatment of benign prostate hyperplasia/lower urinary tract symptoms in patients with different post-void residual urine.
    Luo F; Sun HH; Su YH; Zhang ZH; Wang YS; Zhao Z; Li J
    Lasers Med Sci; 2017 May; 32(4):895-901. PubMed ID: 28293871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary and sexual function after treatment with temporary implantable nitinol device (iTind) in men with LUTS: 6-month interim results of the MT-06-study.
    De Nunzio C; Cantiello F; Fiori C; Crocerossa F; Tognoni P; Amparore D; Baldassarri V; Elbers JR; Sancha FG; Porpiglia F
    World J Urol; 2021 Jun; 39(6):2037-2042. PubMed ID: 32851439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rezum water vapor therapy for patients with mild, moderate, or severe lower urinary tract symptoms: A retrospective study in a multiethnic population.
    Babar M; Loloi J; Tang K; Singh S; Ines M; Patel RD; Iqbal N; Ciatto M
    Prostate; 2023 May; 83(7):713-721. PubMed ID: 36879380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of preoperative detrusor underactivity on long-term surgical outcomes of photovaporization and holmium laser enucleation in men with benign prostatic hyperplasia: a lesson from 5-year serial follow-up data.
    Cho MC; Yoo S; Park J; Cho SY; Son H; Oh SJ; Paick JS
    BJU Int; 2019 May; 123(5A):E34-E42. PubMed ID: 30582661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Singh DV; Mete UK; Mandal AK; Singh SK
    J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of prostatic urethral lift as a minimally invasive therapeutic modality to treat lower urinary tract symptoms while maintaining sexual function in patients with benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials.
    Warli SM; Ikram MF; Sarumpaet RG; Tala ZZ; Putrantyo II
    Arch Ital Urol Androl; 2024 Mar; 96(1):12066. PubMed ID: 38451253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New and Emerging Technologies in Treatment of Lower Urinary Tract Symptoms From Benign Prostatic Hyperplasia.
    Gupta NK; Gange SN; McVary KT
    Sex Med Rev; 2019 Jul; 7(3):491-498. PubMed ID: 29606553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study.
    Roehrborn CG; Gange SN; Shore ND; Giddens JL; Bolton DM; Cowan BE; Brown BT; McVary KT; Te AE; Gholami SS; Rashid P; Moseley WG; Chin PT; Dowling WT; Freedman SJ; Incze PF; Coffield KS; Borges FD; Rukstalis DB
    J Urol; 2013 Dec; 190(6):2161-7. PubMed ID: 23764081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years.
    Sievert KD; Schonthaler M; Berges R; Toomey P; Drager D; Herlemann A; Miller F; Wetterauer U; Volkmer B; Gratzke C; Amend B
    World J Urol; 2019 Jul; 37(7):1353-1360. PubMed ID: 30283994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia: a comparative study of medium- and large-volume prostates.
    Wang M; Guo L; Duan F; Yuan K; Zhang G; Li K; Yan J; Wang Y; Kang H
    BJU Int; 2016 Jan; 117(1):155-64. PubMed ID: 25851432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.